Heteroconjugate antibodies for treatment of hiv infection
CA 2102511 A1 · Owner: Potts, Barbara J. · Inventors: Potts, Barbara J.; Higgins, Paul J.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention features a heteroconjugate antibody which includes two binding functionalities. The first binding function is directed to a peripheral blood effector cell antigen preferably CD-3. , The second functionality is directed to a specific domain of an aids virus coat protein, preferably the V3 loop sequence of the gp120 envelope from HIV MN or a variant thereof. Methods of therapy are also presented where 20 ng/ml of a mixed culture of HIV infected cells (effector/CEM-ss cells) have a 80-90 % decrease in reverse transcriptase activity compared to an identical culture with a 3:1 ratio of effector cell:CEM-ss.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 29, 1992. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended April 29, 2012.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 29, 2014.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.